Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Bayside Health

Status and phase

Completed

Phase 2

Conditions

Non-Hodgkin's Lymphoma (CD20+)

Treatments

Drug: vinorelbine

Drug: rituximab

Drug: ifosfamide

Drug: gemcitabine

Study type

Interventional

Funder types

Other

Identifiers

NCT00280878

AH204/05

Details and patient eligibility

About

This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with Rituximab (R-VGF/R-F-GIV).

Full description

Recent epidemiologic surveys have demonstrated a dramatic increase in the incidence of non-Hodgkin's lymphoma (NHL). NHL is now one of the most rapidly increasing malignancies in the industrial world.

The purpose of this project is to evaluate the efficacy and safety of an outpatient treatment for relapsed or treatment resistant (refractory) CD20+ lymphoma. Two combinations of chemotherapy drugs will be tested depending on the patients prior therapy and response - rituximab, vinorelbine and gemcitabine (R-VGF) OR rituximab, vinorelbine, gemcitabine and ifosfamide (R-FGIV).

Previous experience, including a recently completed study using combinations of vinorelbine, gemcitabine and ifosfamide has demonstrated that such an outpatient approach is safe and of similar efficacy to presently available alternative inpatient chemotherapy approaches. This study is expanding on the findings from the previous study by adding rituximab.

Rituximab is being increasingly and successfully used in the therapy of CD20+ NHL. It is a specific protein (antibody) that is directed against the surface protein (CD20 antigen) found on CD20+ lymphoma cells and can therefore lead to the destruction of these cells. Rituximab also has a highly favourable toxicity profile enabling outpatient treatment.

All of these factors provide a strong rationale for the combination of rituximab and the novel outpatient-based salvage approaches VGF and F-GIV that we have recently evaluated. This pilot study of 12 patients will test the feasibility of this combination approach in patients with relapsed/refractory CD20+ NHL.

Enrollment

12 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age >18 years
Relapsed or primary refractory CD20+ NHL
ECOG 0 - 2
Written informed consent

Exclusion criteria

Intention to proceed with any form of transplant therapy following fewer than 2 cycles of protocol salvage therapy.
Bilirubin > 50µmol/litre unless secondary to lymphoma
Creatinine > 2 x upper limit of normal unless secondary to lymphoma
Absolute neutrophil count <0.5 x 109/litre and / or platelets < 50 x 109/litre unless secondary to lymphoma
Relapse within 6 months of a prior transplant procedure (autologous or allogeneic).
Known sensitivity to E coli derived preparations